Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration
Pascal Biosciences (TSXV:PAS) has announced that it has been licensed by the US Drug Enforcement Administration (DEA) to conduct and research development on cannabinoids.
As quoted in the press release:
Pascal is also pleased to renew the UBC collaboration and continue financial support of Dr. Wilfred Jefferies’ laboratory at the Michael Smith Laboratories.
Pascal is one of only a few organizations with a Schedule I Researcher license in the United States that is not a university. Obtaining a DEA Schedule I Researcher license is a rigorous process, requiring a well-documented line of scientific investigation in a formal application, inspection of laboratory facilities, review of Pascal’s plans for record-keeping, and confirmation of facility security. “Receiving our Schedule I DEA license allows us to immediately conduct advanced R&D on cannabinoids, with a goal of conducting clinical trials on cancer patients as soon as possible”, commented Dr. Patrick Gray, CEO at Pascal.
Dr. Jeffries was the first scientist to discover specific cannabinoids that can increase the immune recognition of both mouse and human cancer cells. Together, both labs have greatly extended this work. Over 375 natural and synthetic cannabinoids have been tested, and the most potent and safe cannabinoids have been identified. “Previous support by Pascal enabled the discovery of specific cannabinoids that enhance detection and elimination of cancers by the immune system”, commented Dr. Jefferies. “Together we have made great progress in developing a cannabinoid for cancer. Pascal’s continued financial support will enable a lead product to complete preclinical efforts for treatment of patients with cancer.”
In order to undertake this work, both the Pascal development lab in Seattle and Dr. Jefferies’ lab in Vancouver, BC were required to be licensed by the appropriate government agencies. In addition to Pascal being awarded the Schedule I Researcher license by the U.S. DEA, Dr. Jefferies’ lab has received approval from Health Canada for an exemption under Section 56 of the Controlled Drugs and Substances Act. This approval allows the lab to utilize controlled substances for research and development purposes and to test cannabinoid compounds in cell-based studies and in animal models of human diseases.
World High Life Plc (“World High Life” or the “Company”)(AQSE:LIFE) (OTCQB:WRHLF), is pleased to announce that it has appointed H&P Advisory Limited (“Hannam & Partners”) as financial advisor to the Company with immediate effect
About Love Hemp
Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ retail stores, today announced that its executive team will participate in the following conference in March 2021:
Needham 2 nd Annual Virtual Cannabis Conference, March 3, 2021: Management will participate in one-on-one meetings.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.